Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 1,736 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Administration first Clear all

Conditions: Chronic Kidney Diseases
Interventions: Zibotentan, Dapagliflozin, Placebo, Dapagliflozin and Zibotentan; Drug
Lead sponsor: University Medical Center Groningen; Other
Eligibility: 18 Years to 75 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Gastric Cancer
Interventions: 5-Fluoruracil, Folinic acid, Onartuzumab, Oxaliplatin, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 564 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 15
States / cities: Los Angeles, California • Denver, Colorado • Fort Myers, Florida + 11 more

Conditions: Chronic Obstructive Pulmonary Disease, COPD, Chronic Bronchitis
Interventions: Inhaled 7% HS (NaCl) home treatment; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 40 Years to 80 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Narcolepsy Type 1 (NT1)
Interventions: VX-433, Placebo, Midazolam, Bupropion; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Rhinovirus Infection
Interventions: VPV 1000 mg, VPV 500 mg, Placebo; Drug · Other
Lead sponsor: Altesa Biosciences, Inc.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 37
States / cities: Mobile, Alabama • Tempe, Arizona • Inglewood, California + 33 more

Conditions: Opioid Use Disorder, Opioid Withdrawal, Substance Use Disorders
Interventions: Ibogaine Hydrochloride, Extended-release naltrexone injection, 380 mg, Matching Oral Placebo, Matching Intramuscular Placebo, My-E-Health SENTINEL Digital Monitoring and Human-Gated Escalation Platform, Standardized Psychological Preparation, Integration and Recovery Support, Garmin-Enabled Longitudinal Wellness Monitoring; Drug · Device · Behavioral + 1 more
Lead sponsor: Clive Michelsen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Basalt, Colorado

Conditions: 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection, COVID-19, COVID-19 Pandemic, COVID-19 Virus Disease, COVID-19 Virus Infection, Covid19, Coronavirus Disease 2019, SARS-CoV2 Infection, SARS-CoV-2 Acute Respiratory Disease
Interventions: Famotidine, Celecoxib, Placebo; Drug
Lead sponsor: Leidos Life Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 15
States / cities: Newport Beach, California • Miami, Florida • Atlanta, Georgia + 12 more

Conditions: Metastatic Breast Cancer
Interventions: Palbociclib, Fulvestrant, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 521 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 134
States / cities: Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 90 more

Conditions: Sub-acute Back Pain
Interventions: Naproxen, Carbidopa/Levodopa, Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Head and Neck Cancer, Radiation Toxicity
Interventions: capsaicin, placebo, radiation therapy; Dietary Supplement · Other · Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2006
U.S. locations: 17
States / cities: Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 14 more

Conditions: Cocaine Dependence
Interventions: JDtic; Drug
Lead sponsor: RTI International; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Obesity
Interventions: Obalon Intragastric Balloons, Sham Device, Nutrition and Lifestyle Program; Device · Behavioral
Lead sponsor: Obalon Therapeutics, Inc.; Industry
Eligibility: 22 Years to 64 Years
Enrollment: 711 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 15
States / cities: Scottsdale, Arizona • Anaheim, California • Coronado, California + 12 more

Conditions: Osteoarthritis, Knee
Interventions: EUFLEXXA™, placebo; Device
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 588 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Epilepsy, Cognitive Deficits, Attention Deficits
Interventions: Methylphenidate; Drug
Lead sponsor: Kimford Jay Meador; Other
Eligibility: 18 Years to 65 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Endometriosis
Interventions: Placebo, OBE2109; Drug
Lead sponsor: ObsEva SA; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 71
States / cities: Chandler, Arizona • Scottsdale, Arizona • Arcadia, California + 59 more

Conditions: Parkinson's Disease
Interventions: High-Frequency Repetitive Transcranial Magnetic Stimulation, Sham Repetitive Transcranial Magnetic Stimulation; Device
Lead sponsor: University of Florida; Other
Eligibility: 30 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Agitation in Patients With Dementia of the Alzheimer's Type
Interventions: AVP-786, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 387 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 111
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 78 more

Conditions: Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions: EUR-1008 (APT-1008), Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 7 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Tyler, Texas

Conditions: HIV -1 Infection
Interventions: GS-0415, GS-0415 Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 16
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Miami Lakes, Florida + 12 more

Conditions: Influenza, Human
Interventions: Flu shot text messages; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 734,383 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Major Depressive Disorder
Interventions: Escitalopram, Placebo, Real-time Neurofeedback fMRI task pre- and post-RCT; Drug · Behavioral
Lead sponsor: Marta Peciña, MD PhD; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Bipolar I Disorder
Interventions: LB-102, Placebo; Drug · Other
Lead sponsor: LB Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 26
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Bellflower, California + 23 more

Conditions: Pancreatitis
Interventions: aprepitant, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Helicobacter Pylori
Interventions: Bismuth quadruple therapy with optimized proton pump inhibitor (PPI), Bismuth quadruple therapy with standard proton pump inhibitor (PPI), Clarithromycin triple therapy with optimized proton pump inhibitor (PPI), Clarithromycin triple therapy with standard PPI, Standard bismuth quadruple therapy; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: San Diego, California

Search by objective public record fields.

Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria

A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer

Sustained Effects of Hypertonic Saline on Mucociliary Clearance in Subjects With Chronic Bronchitis

A Phase 1, First-in-human Study of VX-433

Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD

Medically Supervised Ibogaine With 12-Month Digital Recovery Support for Opioid Use Disorder

Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients

Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)

Effect of L-dopa In Subacute Back Pain Population

Capsaicin Lozenges in Treating Patients With Mucositis Caused by Radiation Therapy

First in Humans Study of JDTic

Obalon Balloon System Pivotal IDE (SMART) Trial

A Study of the Efficacy and Safety of EUFLEXXA™ for Treatment of Painful Osteoarthritis of the Knee

Methylphenidate Treatment of Attention Deficits in Epilepsy

A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis

Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Apathy in Parkinson's Disease

Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

Study of GS-0415 and How It Works in People With HIV

Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates at a Large Retail Pharmacy

Study of Neural Responses Induced by Antidepressant Effects

Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.

A Trial of Aprepitant For Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis

Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans